BioCentury | Jan 22, 2021
Regulation

CAR T Yescarta among new approvals by Japanese regulator

...Autologous T cell therapy against CD19 (KTE-C19) (FKC-876) Adlumiz, anamorelin (ONO-7643, rc-1291) Prolastin (alpha-1 proteinase inhibitor) Gilead Sciences Inc. Ono Pharmaceutical Co. Ltd. Torii...
BioCentury | May 28, 2020
Deals

In its first broad deal, Repare leads BMS deeper into synthetic lethality

...for its two lead programs. Its only other disclosed partnership is a deal 2019 granting Ono Pharmaceutical Co. Ltd....
BioCentury | Apr 3, 2020
Deals

Janssen takes another shot at off-the-shelf CAR Ts with Fate deal

Janssen is adding an off-the-shelf CAR-T and CAR-NK technology to build out its cancer cell therapy pipeline through a deal with Fate Therapeutics, marking at least the second time the company has partnered for allogeneic...
BioCentury | Dec 10, 2019
Clinical News

Investors reward Fate for off-the-shelf NK data at ASH

...three iPS cell-derived allogeneic T cell therapies in development, two of which are partnered with Ono Pharmaceutical Co. Ltd....
BioCentury | Jul 26, 2019
Finance

Earnings on deck

...B) 7/31 NA NA ¥36.98 NA Eisai Co. Ltd. (Tokyo:4523) 7/31 NA NA ¥42.99 NA Ono Pharmaceutical Co. Ltd....
BioCentury | Jul 11, 2019
Company News

July 11 Company Quick Takes: Ono gains Asia rights to Forty Seven's mAb; plus Aimmune, Passage-Paragon and more

...Ono gets local rights to Forty Seven's mAb Forty Seven Inc. (NASDAQ:FTSV) granted Ono Pharmaceutical Co. Ltd. (Tokyo:4528) exclusive...
...Ohr” ). Paul Bonanos, Associate Editor; Hongjiang Li, Staff Writer Catalent Inc. Forty Seven Inc. NeuBase Therapeutics Inc. Ohr Pharmaceutical Inc. Ono Pharmaceutical Co. Ltd. Passage...
BioCentury | Jun 29, 2019
Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

...signs and symptoms of dry eye disease PDUFA date 8/15/19 Karyopharm Therapeutics Inc. (NASDAQ:KPTI) / Ono Pharmaceutical Co. Ltd....
BioCentury | Jun 26, 2019
Company News

June 26 Company Quick Takes: Dupixent approved for nasal polyps; plus Ono/Rafael, Oxford/Santen and more

...Nasal Polyps Data for Dupixent" ). Ono gets Asian rights to cancer cell metabolism candidate Ono Pharmaceutical Co. Ltd....
...oral immunotherapy (oit) CPI-613 Dupixent (Brand), SAR231893 (Compound #), REGN668 (Compound #), dupilumab (Generic), Dupixent (Informal) VGX-3100 Inovio Pharmaceuticals Inc. Ono Pharmaceutical Co. Ltd. Oxford...
BioCentury | May 3, 2019
Finance

Earnings on deck

...NYSE:AMRX) 5/9 Pre $0.18 $0.14 29% Endo International plc (NASDAQ:ENDP) 5/9 Pre $0.43 $0.67 -36% Ono Pharmaceutical Co. Ltd....
BioCentury | Apr 6, 2019
Finance

Big caps under pressure

...Therapeutix Inc. (NASDAQ:OCUL) Sustained-release travoprost Treat open-angle glaucoma or ocular hypertension Phase III data 2Q19 Ono Pharmaceutical Co. Ltd....
Items per page:
1 - 10 of 763
BioCentury | Jan 22, 2021
Regulation

CAR T Yescarta among new approvals by Japanese regulator

...Autologous T cell therapy against CD19 (KTE-C19) (FKC-876) Adlumiz, anamorelin (ONO-7643, rc-1291) Prolastin (alpha-1 proteinase inhibitor) Gilead Sciences Inc. Ono Pharmaceutical Co. Ltd. Torii...
BioCentury | May 28, 2020
Deals

In its first broad deal, Repare leads BMS deeper into synthetic lethality

...for its two lead programs. Its only other disclosed partnership is a deal 2019 granting Ono Pharmaceutical Co. Ltd....
BioCentury | Apr 3, 2020
Deals

Janssen takes another shot at off-the-shelf CAR Ts with Fate deal

Janssen is adding an off-the-shelf CAR-T and CAR-NK technology to build out its cancer cell therapy pipeline through a deal with Fate Therapeutics, marking at least the second time the company has partnered for allogeneic...
BioCentury | Dec 10, 2019
Clinical News

Investors reward Fate for off-the-shelf NK data at ASH

...three iPS cell-derived allogeneic T cell therapies in development, two of which are partnered with Ono Pharmaceutical Co. Ltd....
BioCentury | Jul 26, 2019
Finance

Earnings on deck

...B) 7/31 NA NA ¥36.98 NA Eisai Co. Ltd. (Tokyo:4523) 7/31 NA NA ¥42.99 NA Ono Pharmaceutical Co. Ltd....
BioCentury | Jul 11, 2019
Company News

July 11 Company Quick Takes: Ono gains Asia rights to Forty Seven's mAb; plus Aimmune, Passage-Paragon and more

...Ono gets local rights to Forty Seven's mAb Forty Seven Inc. (NASDAQ:FTSV) granted Ono Pharmaceutical Co. Ltd. (Tokyo:4528) exclusive...
...Ohr” ). Paul Bonanos, Associate Editor; Hongjiang Li, Staff Writer Catalent Inc. Forty Seven Inc. NeuBase Therapeutics Inc. Ohr Pharmaceutical Inc. Ono Pharmaceutical Co. Ltd. Passage...
BioCentury | Jun 29, 2019
Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

...signs and symptoms of dry eye disease PDUFA date 8/15/19 Karyopharm Therapeutics Inc. (NASDAQ:KPTI) / Ono Pharmaceutical Co. Ltd....
BioCentury | Jun 26, 2019
Company News

June 26 Company Quick Takes: Dupixent approved for nasal polyps; plus Ono/Rafael, Oxford/Santen and more

...Nasal Polyps Data for Dupixent" ). Ono gets Asian rights to cancer cell metabolism candidate Ono Pharmaceutical Co. Ltd....
...oral immunotherapy (oit) CPI-613 Dupixent (Brand), SAR231893 (Compound #), REGN668 (Compound #), dupilumab (Generic), Dupixent (Informal) VGX-3100 Inovio Pharmaceuticals Inc. Ono Pharmaceutical Co. Ltd. Oxford...
BioCentury | May 3, 2019
Finance

Earnings on deck

...NYSE:AMRX) 5/9 Pre $0.18 $0.14 29% Endo International plc (NASDAQ:ENDP) 5/9 Pre $0.43 $0.67 -36% Ono Pharmaceutical Co. Ltd....
BioCentury | Apr 6, 2019
Finance

Big caps under pressure

...Therapeutix Inc. (NASDAQ:OCUL) Sustained-release travoprost Treat open-angle glaucoma or ocular hypertension Phase III data 2Q19 Ono Pharmaceutical Co. Ltd....
Items per page:
1 - 10 of 763